E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience
Ohad Benjamini,Hagop M. Kantarjian,Mary Beth Rios,Elias Jabbour,Susan O'Brien,Preetesh Jain,Stefan Faderl,Guillermo Garcia-Manero,Farhad Ravandi,Gautam Borthakur,Alfonso Quintás-Cardama,Jorge E. Cortes +11 more
TL;DR: This single institution experience reflects the heterogeneous nature of pt-driven TKI discontinuation, and characterize the outcome and profile of CML pts who chose to discontinue TKI therapy in a single center regardless of their initial response to TKI Therapy.
Journal ArticleDOI
P576: a phase i/ii study of milademetan (ds3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia
Jatastu Senapati,Jo Ishizawa,H Abbas,Sanam Loghavi,Gautam Borthakur,Ghayas C Issa,Samuel Dara,Rasoul Pourebrahim,Naval Daver,Elias Jabbour,S. Kornblau,Naveen Pemmaraju,G. Garcia-Manero,Farhad Ravandi,Muharrem Muftuoglu,Jean Khoury,Courtney D. DiNardo,Michael Andreeff +17 more
TL;DR: In this paper , the authors evaluated safety and efficacy of milademetan (DS-3032b), an MDM2i, with low dose cytarabine (LDAC) ± venetoclax (VEN) in patients with acute myeloid leukemia (AML).
Journal ArticleDOI
Sorafenib plus 5-azacytidine (AZA) in older untreated FLT3-ITD mutated AML.
Maro Ohanian,Guillermo Garcia-Manero,Mark J. Levis,Elias Jabbour,Naval Daver,Gautam Borthakur,Tapan M. Kadia,Mark Brandt,Sherry Pierce,Jan A. Burger,Mary Ann Richie,Keyur P. Patel,Jorge E. Cortes,Hagop M. Kantarjian,Farhad Ravandi +14 more
TL;DR: Sorafenib plus 5-azacytidine (AZA) is observed to be safe and effective in relapsed / refractory FLT3-ITD mutated acute myeloid leukemia (AML) patients.
Journal ArticleDOI
Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Guillaume Richard-Carpentier,Hagop M. Kantarjian,Marina Konopleva,Keyur P. Patel,Kathryn G. Roberts,Zhaohui Gu,Farhad Ravandi,Nitin Jain,Nicholas J. Short,Guillermo Garcia-Manero,Heather M Schroeder,Monica Kwari,Rebecca Garris,Rita Khouri,Mike Jones,Christopher Loiselle,Jorge E. Cortes,Koji Sasaki,Ghayas C. Issa,Tapan M. Kadia,Courtney D. DiNardo,Srdan Verstovsek,Naval Daver,Charles G. Mullighan,Susan O'Brien,Elias Jabbour +25 more
TL;DR: It is hypothesized that ofatumumab plus Hyper-CVAD may increase the rates of complete remission (CR) and measurable residual disease negativity (MRD-) and improve survival by decreasing relapse rates.
Journal ArticleDOI
Targeting microenvironment-mediated resistance in leukemias: Phase I trial of mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor/g-CSF/sorafenib.
Michael Andreeff,Zhihong Zeng,Mary A. Kelly,Rui-Yu Wang,Teresa McQueen,Seshagiri Duvvuri,Gul Nowshad,Gautam Borthakur,Jan A. Burger,Tapan M. Kadia,Elias Jabbour,Jorge E. Cortes,Hagop M. Kantarjian,Marina Konopleva +13 more
TL;DR: First data testing this concept in patients with R/R FLT3-ITD AML is reported, with an overall response rate of 6/10 and increased in vivo activity of S combined with CXCR4 inhibitor Plerixafor (P) and G-CSF (G).